Modifi Bio Raises Additional $4.3 Million in Seed Funding
16. Oktober 2023 07:00 ET
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second...
ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic
07. Oktober 2022 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian...
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
08. September 2022 08:00 ET
|
Aprea Therapeutics
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
11. August 2022 16:15 ET
|
Aprea Therapeutics
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting in April
30. März 2022 07:00 ET
|
NERx Biosciences
INDIANAPOLIS, March 30, 2022 (GLOBE NEWSWIRE) -- NERx Biosciences, an oncology company led by John Turchi and Katherine Pawelczak, will be presenting on two pre-clinical pipeline drugs that may have...
Cybrexa Therapeutics Announces Expansion of Its Anticancer Pipeline
09. Dezember 2019 08:30 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...
DELFINGEN Industry : Mise à disposition du Document de Référence exercice 2018
29. April 2019 14:45 ET
|
DELFINGEN Industry
MISE A DISPOSITION DE DOCUMENTAnteuil, le 29 avril 2019 DELFINGEN Industry annonce ce jour avoir mis à la disposition du public son Document de Référence au 31 décembre 2018. ...
Foncière INEA : Mise à disposition du Document de Référence et du Rapport RSE 2018
15. April 2019 12:30 ET
|
Foncière Inéa
Mise à disposition du Document de Référence(valant Rapport Financier Annuel) Exercice 2018 Paris, le 15 avril 2019 Foncière INEA (ISIN : FR0010341032), société d’investissement...
ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
10. April 2018 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...
Simplify Industrial-Grade Linux® Designs with SAMA5D2 MPU-Based System On Module (SOM)
20. Februar 2018 03:00 ET
|
Microchip Technology Incorporated
CHANDLER, Ariz., Feb. 20, 2018 (GLOBE NEWSWIRE) -- There is a great deal of design effort and complexity associated with creating an industrial-grade microprocessor (MPU)-based system running a...